Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGV354 · 1 trial · 2 indications
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Diurnal IOP was defined as the average of the five time points measured (8 AM, 10 AM, noon, 4 PM, and 8 PM). Baseline diurnal IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8 and averaging the available changes. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Baseline IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.
| Arm | Type | Description |
|---|---|---|
| MGV354 | EXPERIMENTAL | Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days |
| Placebo | PLACEBO_COMPARATOR | Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days |
| Name | Type | Description |
|---|---|---|
| MGV354 ophthalmic suspension | DRUG | - |
| MGV354 placebo | DRUG | Inactive ingredients used as placebo comparator |
Inclusion Criteria: * Documented informed consent. * Part 1: 18 to 70 years of age; * Parts 2 and 3: 18 years of age or older; * Able to communicate well with the investigator and understand and comply with the requirements of the study; * Body Mass Index (BMI) between 18 and 39; * In case of conta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
MGV354 is an investigational small molecule being developed for ocular hypertension, a condition of elevated pressure inside the eye. It was studied in a Phase 1 clinical trial that also included patients with open-angle glaucoma. The drug is administered to lower intraocular pressure, though it remains in clinical development and is not yet approved.
MGV354 is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a pharmaceutical company focused on eye care and ophthalmology products. The drug is currently in Phase 1 clinical development for ocular hypertension.
MGV354 is in Phase 1 clinical development. A Phase 1 trial of the drug has been completed, involving 191 participants. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of ocular hypertension and open-angle glaucoma.
MGV354 has one completed clinical trial registered under the identifier NCT02743780. The trial, titled 'A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma,' was a Phase 1, randomized, double-blind, placebo-controlled study that enrolled 191 participants aged 18 years and older.
MGV354 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a small molecule being developed by Alcon Inc. for ocular hypertension and open-angle glaucoma, and it is currently in Phase 1 clinical development.